This spring, Walmart will convert a select group of its stores and recently closed outpatient health centers into clinical research sites, marking the company’s first major entry into patient-facing trials. The pilot program will roll out in eight locations across three states—Texas, Florida and Ohio—and is expected to recruit up to 2,000 participants over the next 12 months. Walmart aims to leverage its existing pharmacy infrastructure and in-store lab facilities to reduce overhead by an estimated 30% compared with traditional contract research organizations, while driving additional foot traffic and strengthening its value proposition in healthcare services.

Walmart has expanded its third-party Marketplace platform by introducing a dedicated Musical Instruments storefront, featuring over 1,200 SKUs from two dozen specialty brands. The initiative is designed to boost the platform’s average transaction value, which currently lags behind peers by 18%, and to attract a more affluent demographic segment. Internal forecasts project that the new category could account for up to 4% of Marketplace gross merchandise volume by year-end, contributing incremental annual revenue of roughly $150 million. Walmart will also offer fulfillment services for participating vendors, aiming to shorten delivery times to three days or less in 75% of U.S. ZIP codes.

A recent proprietary analysis using valuation, sentiment and operational momentum factors has flagged Walmart as overvalued relative to peers, assigning the stock a neutral stance with a downside target price of $83 per share. The model scores Walmart most heavily on decelerating same-store sales trends—projected to slow to 1.5% annual growth this fiscal year—and narrowing e-commerce margins, which fell 120 basis points last quarter. While the company’s broad geographic reach and consistent dividend policy underpin its defensive appeal, the evaluation concludes that downside risk outweighs upside catalysts over the next 9–12 months.